Words matter during a heart attackRecent research suggests that the ways in which men and women describe heart attack symptoms differently can affect Share XWords matter during a heart attackhttps://pharmaphorum.com/views-analysis-patients/words-matter-during-heart-attack/
Patient-partnered drug discovery: vision or reality?pharmaphorum’s Paul Tunnah talks to Anthony Yanni, newly appointed senior vice president & global head of patient centricity, Share XPatient-partnered drug discovery: vision or reality?https://deep-dive.pharmaphorum.com/magazine/patient-engagement/astellas-patient-partnered-drug-discovery-vision-or-reality/
Deep Dive: Patient EngagementPatient engagement has moved from a lofty goal to a tangible part of most pharma companies’ businesses – Share XDeep Dive: Patient Engagementhttps://pharmaphorum.com/views-and-analysis/deep-dive-patient-engagement/
How to address racial disparities in clinical trial dataIn the US, fewer than three per cent of eligible patients participate in clinical trials – a figure Share XHow to address racial disparities in clinical trial datahttps://pharmaphorum.com/views-analysis-patients/utilising-technology-racial-disparities-clinical-trial-data/
Patient Insights: Colorectal CancerEvent planner and colorectal cancer survivor Kim Hall-Jackson tells us how she hopes to improve rates of diagnosis, Share XPatient Insights: Colorectal Cancerhttps://pharmaphorum.com/views-analysis-patients/patient-insights-colorectal-cancer/
Q&A: Accenture’s Keena Patel on optimising patient engagementWe speak to Keena Patel, a managing director in Accenture’s Life Sciences practice, about how pharmaceutical companies can Share XQ&A: Accenture’s Keena Patel on optimising patient engagementhttps://pharmaphorum.com/views-analysis-patients/accentures-keena-patel-patient-engagement/
Joined up thinking and innovation will boost drug development in rare diseasesFresh thinking and greater collaboration at the European level could accelerate the much-needed development of treatments and cures Share XJoined up thinking and innovation will boost drug development in rare diseaseshttps://pharmaphorum.com/views-analysis-patients/innovation-drug-development-rare-diseases/
Where next for patient centricity in pharma?As patient centricity seems to be hitting a slump, Paul Tunnah lays out the key factors companies need Share XWhere next for patient centricity in pharma?https://pharmaphorum.com/views-analysis-patients/where-next-for-patient-centricity-in-pharma/
A blueprint for building a patient-centric pharma companyWhile the industry appears united in its commitment to patient centricity, the practicalities of embedding the ethos into Share XA blueprint for building a patient-centric pharma companyhttps://pharmaphorum.com/views-analysis-patients/whitepaper-provides-a-blueprint-to-building-a-patient-centricity-company/
